Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
July 31, 2011
Primary Completion Date
November 30, 2011
Study Completion Date
February 29, 2012
Conditions
Inflammation
Interventions
DRUG
XG-102
single intravenous infusion
Trial Locations (1)
4123
Covance Clinical Research, Allschwil
All Listed Sponsors
lead
Xigen SA
INDUSTRY
NCT01570205 - Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers | Biotech Hunter | Biotech Hunter